BioNTech’s Triple Transformation: Factory Closures, Founder Exit and a Make-or-Break Cancer Trial

As COVID vaccine demand collapses, BioNTech slashes 1,860 jobs, founders plan exit, and key Phase 2 cancer data at ASCO will test its future as an oncology contender.

The next three weeks will test whether BioNTech can successfully pivot from pandemic poster child to oncology contender. With production lines grinding to a halt, its founders preparing to walk away, and the first major clinical readout for its lead cancer drug looming, the German biotech is navigating a series of inflection points that will define its future.

The numbers behind the shift are stark. First?quarter revenue slumped to €118.1 million from €182.8 million a year earlier, underscoring the collapse in COVID?19 vaccine demand. That translated into a net loss of roughly €532 million. Despite the red ink, the company reaffirmed its full?year guidance of €2.3?billion to €2.6?billion and authorised a $1?billion share buyback programme spanning 12 months.

The austerity plan is equally aggressive. By 2027, BioNTech will close sites in Marburg, Idar-Oberstein, Tübingen and Singapore, cutting around 1,860 jobs – nearly a quarter of its 8,400?strong workforce. The vaccine production that made it a household name will be completely wound down by 2026.

At the same time, the boardroom is being reshaped for a post?founder era. At the virtual annual general meeting on 15?May, shareholders will vote to enlarge the supervisory board from six to eight members, bringing in two clinical?development specialists to oversee the succession of chief executive U?ur ?ahin and chief medical officer Özlem Türeci. The couple plans to leave BioNTech by the end of 2026 to launch a new mRNA spin?off. A binding contract is expected in the first half of that year, under which BioNTech will contribute related rights and mRNA technologies at market terms in exchange for a minority stake, milestone payments and royalties.

A separate resolution covers a new authorised capital of up to €129.5?million – equivalent to 50% of current share capital – replacing the existing 2025 authorisation. Meanwhile, a domination and profit?transfer agreement with subsidiary BioNTech Discovery GmbH aims to consolidate tax affairs, allowing profits from the unit to offset the parent’s losses. For a group that posted a net loss of €1.14?billion in fiscal 2025, that is more than a procedural formality. No dividend has been proposed; the company will carry forward its entire retained earnings of roughly €6.9?billion.

Investors so far appear to give management the benefit of the doubt. The stock rose 2.2% on Monday to €81.20, just shy of its 50?day moving average of €82.74. Technicians see a break above that level as an early confirmation that the strategic overhaul is gaining traction. Still, the shares trade about 21% below their 52?week high set last June, reflecting the market’s wait?and?see attitude toward the oncology pipeline.

That patience will be tested at the American Society of Clinical Oncology (ASCO) meeting from 29?May to 1?June. BioNTech will present Phase?2 data from the ROSETTA?Lung?02 study, pitting its lead candidate pumitamig in combination with chemotherapy against the established standard pembrolizumab plus chemotherapy in first?line non?small cell lung cancer. A second trial, in small?cell lung cancer, was launched in April under a clinical collaboration with Boehringer Ingelheim, combining pumitamig with Boehringer’s DLL3/CD3 T?cell engager obrixtamig.

Pumitamig is part of a broader oncology push that also includes the candidate gotistobart and a separate Phase?2 candidate, trastuzumab pamirtecan, targeting a specific form of uterine cancer. Research?and?development spending jumped to €557?million in the first quarter, driven almost entirely by these programmes. The capital freed from the vaccine business is being redirected into a pipeline that could take years – and billions of euros per drug – to yield commercial returns. For now, the ASCO readout will provide the first hard evidence of whether BioNTech’s bet on cancer can replicate its success with COVID?19.